New Study Underscores Rapidity of Oral Drug Bio-delivery Using Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Technology as an Alternative to Smoking and Vaping

• Oral drug delivery innovator Lexaria Bioscience is focused on providing alternatives to smoked or inhaled tobacco and cannabis products to help consumers reduce the threat to their lungs
• Lexaria’s patented technology — DehydraTECH(TM) — is a solution that processes active pharmaceutical ingredients into a powder or liquid form that can then be ingested with less harm than inhalation, while providing rapidity similar to inhalation substances
• DehydraTECH has previously shown the ability to move CBD into test subjects’ bloodstreams up to 20-fold higher than standard generic formulations
• New testing shows that DehydraTECH can similarly deliver THC to test subjects’ bloodstreams at rates faster and well above those of standard formulations for oral THC use

A leader in innovative drug delivery platforms, Lexaria Bioscience (NASDAQ: LEXX) aims to reduce or eliminate the use of inhaled and addictive products by focusing on ways to deliver nicotine into smokers’ bloodstreams at levels comparable to the nerve-settling relief they get from cigarettes and other tobacco products, providing them an alternative to purchasing store brands likely to harm their lungs. The company has enhanced its pursuit by testing its solution — its patented DehydraTECH technology — as an alternative to smoked or vaped cannabis products as well, and is reporting continued breakthroughs in… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CanadianCannabisWire CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CanadianCannabisWire.com Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer Do you have questions or are you interested in working with CNW? Ask our Editor CanadianCannabisWire (CNW) Toronto, Ontario www.CanadianCannabisWire.com 905.674.5977 Office [email protected] CanadianCannabisWire is part of the InvestorBrandNetwork.